Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

64.45
-1.9600-2.95%
Pre-market: 65.871.42+2.20%04:25 EDT
Volume:1.85M
Turnover:119.64M
Market Cap:12.46B
PE:170.06
High:65.78
Open:65.78
Low:63.85
Close:66.41
52wk High:70.98
52wk Low:49.26
Shares:193.27M
Float Shares:192.12M
Volume Ratio:1.08
T/O Rate:0.96%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3790
EPS(LYR):1.80
ROE:1.18%
ROA:3.26%
PB:1.97
PE(LYR):35.81

Loading ...

BioMarin price target lowered to $97 from $98 at BMO Capital

TIPRANKS
·
Yesterday

BioMarin to discontinue development of Voxzogo for children with Noonan syndrome

TIPRANKS
·
Yesterday

Biomarin Pharmaceutical - Discontinues Development of Voxzogo for Children with Noonan Syndrome on Sept 15, 2026 - SEC Filing

THOMSON REUTERS
·
Yesterday

BioMarin Files Form 3 for Director Robert M. Plenge, Reporting no Beneficial Ownership

Reuters
·
Yesterday

BioMarin Appoints Bristol Myers Squibb Research Chief Robert Plenge to Board

Reuters
·
Sep 14

Biomarin Announces Appointment of Robert Plenge, M.d., Ph.d., Chief Research Officer of Bristol Myers Squibb, to Board of Directors

THOMSON REUTERS
·
Sep 14

Press Release: BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors

Dow Jones
·
Sep 14

Growth Without AI: 8 Stock Picks

Dow Jones
·
Sep 11

BioMarin Pharmaceutical Price Target Maintained with a $60.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 10

BioMarin reports new data from Phase 3 CANOPY-HCH-3 study

TIPRANKS
·
Sep 09

BioMarin Submits FDA sNDA to Expand Voxzogo Use to Children with Hypochondroplasia

Reuters
·
Sep 09

Biomarin Announces Positive Results of Phase 3 Voxzogo® (Vosoritide) Study in Hypochondroplasia Published in Nejm Evidence

THOMSON REUTERS
·
Sep 09

Clearway Energy Names Steven Ryder CFO Effective Oct. 1

Reuters
·
Sep 09

BioMarin Chief Legal Officer George Eric Davis Disposes of 17,557 Shares Worth $1.16 Million

Reuters
·
Sep 04

BioMarin Management Presents at Wells Fargo Healthcare Investor Conference

Reuters
·
Sep 02

CASI Pharmaceuticals Sells Alesta Stake to BioMarin for Us$5.9 Million

Reuters
·
Sep 02

How BioMarin’s Navepegritide Settlement and Royalty Deal with Ascendis Could Shape BioMarin (BMRN) Investors

Simply Wall St.
·
Sep 02

Barfresh Food Names CEO Delle Coste Interim CFO as Lisa Roger Retires

Reuters
·
Sep 02

BioMarin Pharmaceutical is Maintained at Overweight by Piper Sandler

Dow Jones
·
Sep 02

Biomarin Announces Close of the Alesta Therapeutics Acquisition

THOMSON REUTERS
·
Sep 01